Innovative COVID-19 Products Exonbio’s rapid development and launch of SARS-CoV-2 spike recombinant monoclonal antibodies demonstrate their agility and technical expertise, presenting opportunities to collaborate on next-generation COVID-19 diagnostics and therapeutics.

Niche Biotech Focus Specializing in recombinant antibodies and proteins with proprietary SPIN technology positions Exonbio as a potential partner for custom antibody sourcing, research collaborations, and high-specificity assay development for various biotech and pharmaceutical clients.

Growing Market Footprint With revenue in the $1 million to $10 million range and recent product launches, Exonbio is expanding its client base and market presence, offering prospects for sales partnerships, distribution channels, or joint ventures to accelerate growth.

Technological Edge The company's use of advanced biotech platforms and proprietary technologies indicates a strong R&D capability, making them suitable for collaborations on innovative projects needing cutting-edge recombinant protein and antibody solutions.

Potential for Custom Solutions Exonbio’s focus on high-affinity antibody production and recombinant proteins aligns with the needs of research organizations, pharmaceutical firms, and diagnostic companies seeking tailored, high-quality biotech reagents and assay components.